UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Item 1.

Security and Issuer

                                                This Statement is being filed with respect to the common stock, $0.01 par value per share (the “Common Stock”), of Bruker Corporation, a Delaware corporation (the “Company”).  The address of the principal executive offices of the Company is 40 Manning Road, Billerica, MA 01821.

Item 2.

Identity and Background

(a)               This statement is filed by and on behalf of Frank H. Laukien, Ph.D. (the “Reporting Person”).

(b)              The address of the principal business and principal office of the Reporting Person is c/o Bruker Corporation, Billerica, Massachusetts 01821.

(c)               The Reporting Person is the President and Chief Executive Officer, as well as the Chairman of the board of directors, of the Company.

(d)              During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)               During the last five years, the Reporting Person has not been a party to civil proceeding of a judicial administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)                 The Reporting Person is a citizen of the United States and of Germany.

Item 3.

Source and Amount of Funds or Other Consideration

                                                Prior to February 26, 2008, the Reporting Person beneficially owned 19,547,838 shares of Common Stock of the Company, including 1,064,276 shares owned by the Reporting Person’s former spouse over which the Reporting Person has voting power. Beneficial ownership of such shares was previously reported on an amended Schedule 13G filed with the Securities and Exchange Commission (the “Commission”) on February 13, 2008. On February 26, 2008, in connection with the closing of the acquisition of the Bruker BioSpin Group by the Company (the “Acquisition”), the Reporting Person received 10,034,387 shares, and his former spouse received 755,276 shares over which the Reporting Person has voting power, of unregistered restricted Common Stock of the Company as consideration for 18.75% of the equity of Bruker BioSpin Invest AG, a Swiss stock corporation. Subsequent to the closing of the Acquisition, on February 26, 2008 the Reporting Person acquired 5,520,187 additional shares, and his former spouse acquired 296,757 additional shares over which the Reporting Person has voting power, of unregistered restricted Common Stock of the Company from certain Laukien family members for aggregate consideration of $50,454,507 and $2,712,360, respectively, in private transactions pursuant to a Cash-Stock Exchange Agreement dated as of December 2, 2007 (the “CSX Purchases”). Cash proceeds of the Acquisition were used to fund the CSX Purchases. The Acquisition and the Cash-Stock Exchange Agreement are more fully described in the Proxy Statement on Schedule 14A filed with the Commission on January 17, 2008.

                                                As a result of the foregoing transactions, the Reporting Person beneficially owns 36,154,445 shares of Common Stock of the Company, including 2,116,309 shares held by his former spouse over which he has voting control.

Item 4.

Purpose of Transaction

                                                The Reporting Person acquired the shares of Common Stock for investment purposes. The Reporting Person has no plans or proposals which relate to or would result in any of the actions enumerated in the instructions to Item 4 of Schedule 13D.

Item 5.

Interest in Securities of the Issuer

                                                The aggregate number and percentage of shares of Common Stock beneficially owned by the Reporting Person calculated as described below is as follows:

(a)               Amount beneficially owned:  36,154,445

(b)              Percent of class:  22.2%

(c)               Number of shares as to which the person has:

                                                (i)                                     Sole power to vote or to direct the vote:  36,154,445

                                                (ii)                                  Shared power to vote or to direct the vote:  0

                                                (iii)                               Sole power to dispose or to direct the disposition of:  34,038,136

                                                (iv)                              Shared power to dispose or to direct the disposition of:  2,116,309

                                                The percent of class specified above (and in the cover pages to this Statement) is calculated on the basis of 105,670,237 shares of Common Stock issued and outstanding as reported in the Company’s Schedule 14A filed with the Commission on January 17, 2008, increased by the aggregate number of 57,544,872 shares of Common Stock issued upon the closing of the Acquisition.

                                                Except as set forth above, the Reporting Person has not effected any transactions in the Common Stock during the 60 days preceding the date of this Statement.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

                                                Pursuant to the terms of the Agreement and Plan of Merger dated as of December 2, 2007 (the “Swiss Merger Agreement”) by and among the Company, Bruker BioSpin Beteiligungs AG, Bruker BioSpin Invest AG and the Laukien family shareholders of Bruker BioSpin Invest AG (the “Invest Shareholders”), the Reporting Person, his former spouse, and the other Invest Shareholders agreed that they will not sell, pledge, or otherwise dispose of, the shares of Common Stock received as consideration for the Acquisition, other than in connection with certain transfers purely amongst themselves, for a period of 365 days after the Acquisition closing date. 

                                                Except for the Swiss Merger Agreement described above and the voting agreement between the Reporting Person and his former spouse, pursuant to which the Reporting Person has voting power over the Common Stock held by the Reporting Person’s former spouse, the Reporting Person is not a party to any contract, arrangement, understanding or relationship (legal or otherwise) with any person with respect to any securities of the Company, including, but not limited to, any agreement concerning (i) transfer or voting of any securities of the Company, (ii) finder's fees, (iii) joint venture, (iv) loan or option arrangements, (v) puts or calls, (vi) guarantees of profits, (vii) divisions of profits or losses, or (viii) the giving or withholding of proxies.

Item 7.

Material to be Filed as Exhibits

                                                I.                                         Agreement and Plan of Merger dated as of December 2, 2007 by and among the Company, Bruker BioSpin Beteiligungs AG, Bruker BioSpin Invest AG and the Invest Shareholders (incorporated by reference to Annex A-3 to the Company’s Proxy Statement on Schedule 14A filed with the Commission on January 17, 2008)

Dated: February 29, 2008

 /s/ Frank H. Laukien

FRANK H. LAUKIEN, PH.D.